Conservative Versus Liberal Red Cell Transfusion in Myocardial Infarction Trial: The CRIT Pilot (CRIT)

July 20, 2011 updated by: Medstar Health Research Institute
The purpose of this trial is to determine whether a conservative or a liberal blood transfusion strategy is better for patients with a heart attack and a low blood count.

Study Overview

Status

Completed

Detailed Description

The current standard of care for patients with heart attacks is to transfuse red blood cells when the hematocrit (red blood cell count) drops below 30 percent. However, there is little scientific basis for this current standard, and recent research has demonstrated that it is safe to allow the hematocrit (red blood cell count) to drop significantly lower in severely ill medical patients and in patients with heart disease undergoing major surgery. The investigators therefore propose this pilot trial to begin to determine whether or not it is safe to apply a more conservative blood transfusion strategy to patients with heart attacks.

In this study, patients who are within 72 hours of the onset of a heart attack and who are anemic (have a low red blood cell count) will be randomly assigned to one of two transfusion strategies while they are in the hospital: a liberal strategy of transfusing blood when the hematocrit falls below 30 percent (the current standard) or a conservative strategy of transfusing blood only when the hematocrit falls below 24 percent. It will then be determined which group fares better over the next 30 days.

The plan is to enroll 92 patients in this pilot trial in order to allow the researchers to plan for a much larger, definitive trial of this important question. It is anticipated that the conservative transfusion strategy will be similar to the standard (liberal) strategy in terms of patient outcomes.

Study Type

Interventional

Enrollment (Actual)

45

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • District of Columbia
      • Washington, District of Columbia, United States, 20010
        • Washington Hospital Center
      • Washington, District of Columbia, United States, 20010
        • Washington VA Medical Center
    • North Carolina
      • Durham, North Carolina, United States
        • Durham VA Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

All of the following must be present:

  • Acute myocardial infarction with presentation within 72 hours of randomization (acute myocardial infarction is defined as ischemic-type chest discomfort lasting at least 30 minutes associated with creatinine kinase MB (CKMB) or troponin >upper limit of normal [ULN])
  • Admission to CCU
  • Hematocrit .30 or less
  • Written, informed consent

Exclusion Criteria:

  • Inability or unwillingness to receive red cell transfusions
  • Active bleeding (overt blood loss accompanied by a decrease in hematocrit of at least 5% in the preceding 12 hours)
  • Receipt of red cell transfusion within 7 days of randomization
  • Prior severe transfusion reaction
  • Pregnancy
  • Imminent death
  • Decision to provide limited care
  • Age <21
  • Participation in another clinical trial in which blood transfusion is a requirement or a component of a primary or secondary endpoint
  • Previous participation in the CRIT Pilot

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: 1
Liberal transfusion threshold
transfusion of 1 unit of PRBCs
Experimental: 2
Conservative transfusion threshold
transfusion of 1 unit of PRBCs

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
In-hospital death
Time Frame: In-hospital
In-hospital
Recurrent myocardial infarction (MI)
Time Frame: In-hospital
In-hospital
New or worsening heart failure
Time Frame: In-hospital
In-hospital

Secondary Outcome Measures

Outcome Measure
Time Frame
Death at 30 days
Time Frame: 30 days
30 days
Critical Care Unit (CCU) length of stay
Time Frame: In-hospital
In-hospital
Length of hospitalization
Time Frame: In-hospital
In-hospital
Death or recurrent MI at hospital discharge and 30 days
Time Frame: 30 days
30 days
Death or recurrent MI or new or worsening congestive heart failure (CHF) at 30 days
Time Frame: 30 days
30 days
In-hospital recurrent ischemia
Time Frame: In-hospital
In-hospital
In-hospital death or recurrent MI or new or worsening CHF or recurrent ischemia
Time Frame: In-hospital
In-hospital
Acute renal insufficiency (increase in serum creatinine of ≥ 0.5mg/dL)
Time Frame: In-hospitall
In-hospitall
Number of transfusions received per patient
Time Frame: In-hospital
In-hospital
Proportion of patients receiving at least one transfusion
Time Frame: In-hospital
In-hospital
Mean daily hematocrit
Time Frame: In-hospital
In-hospital
Transfusion-related reactions
Time Frame: In-hospital
In-hospital

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Howard A Cooper, M.D., Medstar Health Research Institute

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2003

Primary Completion (Actual)

December 1, 2010

Study Completion (Actual)

January 1, 2011

Study Registration Dates

First Submitted

August 2, 2005

First Submitted That Met QC Criteria

August 2, 2005

First Posted (Estimate)

August 3, 2005

Study Record Updates

Last Update Posted (Estimate)

July 21, 2011

Last Update Submitted That Met QC Criteria

July 20, 2011

Last Verified

July 1, 2011

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe